Autoreactive antibody production by intrarenal B cells in mouse kidney allograft rejection

Antibody-mediated rejection (AMR) is a major cause of kidney allograft failure, with donor HLA-specific antibodies (DSA) recognized as primary drivers of AMR pathology. However, a significant proportion of AMR diagnoses lack detectable DSA, thus implicating DSA-independent mechanisms. In support, we previously reported on the accumulation of autoreactive B cells in rejecting renal biopsies, which raised the possibility that autoreactive IgG produced within the allograft contributes to graft pathology. In this study, we used mouse models to show that rejecting kidney allografts preferentially promoted a breach in autoreactive B cell tolerance, leading to the local production of autoreactive antibodies. Notably, autoreactive IgG responses were uncoupled from DSA production, indicative of distinct regulation. Organoid cultures confirmed that autoantibody production was observed in the rejecting kidney, whereas DSAs were produced in both the lymph node and graft. Intrarenal B cells expressing Nur77 were enriched for autoreactivity, consistent with in situ antigen recognition. Finally, autoreactive antibodies are pathogenic, since inhibiting autoantibody production with transient anti-IL-15 and CTLA-4Ig led to preserved kidney allografts. These unique features of in situ autoantibody responses may be relevant to diverse diseases with chronic tissue inflammation beyond transplantation.